Literature DB >> 28797781

Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?

Rashmika Potdar1, Gabor Varadi1, Joshua Fein2, Myriam Labopin3, Arnon Nagler4, Roni Shouval5.   

Abstract

Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment for many hematologic disorders. Maximizing the benefit of transplantation for disease control while minimizing the risk for associated complications remains the field's leading challenge. This challenge has prompted the development of multiple prognostic scoring systems over the last 2 decades. Prognostic scores can be used for informed decision making, better patient counseling, design of interventional trials, and analysis of prospective and retrospective data. They are also helpful in treatment allocation and personalization according to predicted risk. A better understanding of the molecular and cytogenetic features of the disease, along with the advent of novel therapies, has increased the need for reliable prognostication of which patients will benefit most from transplantation. Here we review the clinical role of the prognostic systems currently in clinical use, examining both their strengths and their limitations.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Nonrelapse mortality; Prognosis; Risk score

Mesh:

Year:  2017        PMID: 28797781     DOI: 10.1016/j.bbmt.2017.07.028

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

1.  External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

Authors:  Roni Shouval; Joshua A Fein; Aniela Shouval; Ivetta Danylesko; Noga Shem-Tov; Maya Zlotnik; Ronit Yerushalmi; Avichai Shimoni; Arnon Nagler
Journal:  Blood Adv       Date:  2019-06-25

2.  Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation.

Authors:  Nelli Bejanyan; Claudio G Brunstein; Qing Cao; Aleksandr Lazaryan; Celalettin Ustun; Erica D Warlick; Mukta Arora; John E Wagner; Daniel J Weisdorf
Journal:  Blood Adv       Date:  2019-02-12

3.  Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Authors:  Alexandros Spyridonidis; Myriam Labopin; Bipin N Savani; Riitta Niittyvuopio; Didier Blaise; Charles Craddock; Gerard Socié; Uwe Platzbecker; Dietrich Beelen; Noel Milpied; Jan J Cornelissen; Arnold Ganser; Anne Huynh; Laimonas Griskevicius; Sebastian Giebel; Mahmoud Aljurf; Eolia Brissot; Florent Malard; Jordi Esteve; Zinaida Peric; Frédéric Baron; Annalisa Ruggeri; Christoph Schmid; Maria Gilleece; Norbert-Claude Gorin; Francesco Lanza; Roni Shouval; Jurjen Versluis; Gesine Bug; Yngvar Fløisand; Fabio Ciceri; Jamie Sanz; Ali Bazarbachi; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-01-29       Impact factor: 5.483

4.  Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study.

Authors:  Sheng-Min Wang; Sung-Soo Park; Si-Hyun Park; Nak-Young Kim; Dong Woo Kang; Hae-Ran Na; Jong Wook Lee; Seunghoon Han; Hyun Kook Lim
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

5.  A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction.

Authors:  Kalyan Nadiminti; Kimberly Langer; Ehsan Shabbir; Mehrdad Hefazi; Lindsay Dozeman; Yogesh Jethava; Bradley Loeffler; Hassan B AlKhateeb; Mark Litzow; Mrinal Patnaik; Mithun Shah; William Hogan; Umar Farooq; Margarida Silverman; Sarah L Mott
Journal:  Blood Cancer J       Date:  2021-11-20       Impact factor: 11.037

6.  Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning-Based Model Development and Validation.

Authors:  Eun-Ji Choi; Tae Joon Jun; Han-Seung Park; Jung-Hee Lee; Kyoo-Hyung Lee; Young-Hak Kim; Young-Shin Lee; Young-Ah Kang; Mijin Jeon; Hyeran Kang; Jimin Woo; Je-Hwan Lee
Journal:  JMIR Med Inform       Date:  2022-03-07

7.  External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study.

Authors:  Nicolas Fattinger; Jan A Roth; Helen Baldomero; Daiana Stolz; Michael Medinger; Dominik Heim; Michael Tamm; Jörg P Halter; Jakob R Passweg; Martina Kleber
Journal:  Hemasphere       Date:  2022-03-11

8.  The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.

Authors:  Roni Shouval; Joshua A Fein; Christina Cho; Scott T Avecilla; Josel Ruiz; Ana Alarcon Tomas; Miriam Sanchez-Escamilla; Nerea Castillo Flores; Lucrecia Yáñez; Juliet N Barker; Parastoo Dahi; Sergio A Giralt; Alexander I Geyer; Boglarka Gyurkocza; Ann A Jakubowski; Richard J Lin; Richard J O'Reilly; Esperanza B Papadopoulos; Ioannis Politikos; Doris M Ponce; Craig S Sauter; Michael Scordo; Brian Shaffer; Gunjan L Shah; James P Sullivan; Roni Tamari; Marcel R M van den Brink; James W Young; Arnon Nagler; Sean Devlin; Avichai Shimoni; Miguel-Angel Perales
Journal:  Blood Adv       Date:  2022-03-08

9.  Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study.

Authors:  Jérémie Héritier; Michael Medinger; Dominik Heim; Helen Baldomero; Christian Arranto; Jörg P Halter; Jakob R Passweg; Martina Kleber
Journal:  Bone Marrow Transplant       Date:  2022-02-08       Impact factor: 5.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.